JP2013529178A5 - - Google Patents

Download PDF

Info

Publication number
JP2013529178A5
JP2013529178A5 JP2012557275A JP2012557275A JP2013529178A5 JP 2013529178 A5 JP2013529178 A5 JP 2013529178A5 JP 2012557275 A JP2012557275 A JP 2012557275A JP 2012557275 A JP2012557275 A JP 2012557275A JP 2013529178 A5 JP2013529178 A5 JP 2013529178A5
Authority
JP
Japan
Prior art keywords
composition
protein
fusion protein
polynucleotide encoding
antagonist peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012557275A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013529178A (ja
JP5975886B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/028070 external-priority patent/WO2011112915A2/en
Publication of JP2013529178A publication Critical patent/JP2013529178A/ja
Publication of JP2013529178A5 publication Critical patent/JP2013529178A5/ja
Application granted granted Critical
Publication of JP5975886B2 publication Critical patent/JP5975886B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012557275A 2010-03-11 2011-03-11 Ｆｃ融合タンパク質を含む、免疫応答を増強するための方法および組成物 Active JP5975886B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31298210P 2010-03-11 2010-03-11
US61/312,982 2010-03-11
PCT/US2011/028070 WO2011112915A2 (en) 2010-03-11 2011-03-11 Methods and compositions containing fc fusiong proteins for enhancing immune responses

Publications (3)

Publication Number Publication Date
JP2013529178A JP2013529178A (ja) 2013-07-18
JP2013529178A5 true JP2013529178A5 (enExample) 2014-05-01
JP5975886B2 JP5975886B2 (ja) 2016-08-23

Family

ID=44564143

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012557275A Active JP5975886B2 (ja) 2010-03-11 2011-03-11 Ｆｃ融合タンパク質を含む、免疫応答を増強するための方法および組成物

Country Status (5)

Country Link
US (1) US9296803B2 (enExample)
EP (1) EP2545174B1 (enExample)
JP (1) JP5975886B2 (enExample)
CN (1) CN102884194B (enExample)
WO (1) WO2011112915A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6397479B2 (ja) 2013-03-15 2018-09-26 エータイアー ファーマ， インコーポレイテッド ヒスチジル−ｔＲＮＡシンテターゼＦｃコンジュゲート
CA3045302A1 (en) * 2016-11-29 2018-06-07 Health Research, Inc. Methods and compositions for cancer therapy
EP3612215B1 (en) 2017-04-20 2024-08-28 aTyr Pharma, Inc. Compositions for treating lung inflammation
RU2676317C1 (ru) * 2017-08-30 2018-12-27 федеральное государственное автономное образовательное учреждение высшего образования Первый Московский государственный медицинский университет имени И.М. Сеченова Министерства здравоохранения Российской Федерации (Сеченовский университет) ГЕНЕТИЧЕСКАЯ КОНСТРУКЦИЯ pCXCRs-Fc ДЛЯ ПОЛУЧЕНИЯ РЕКОМБИНАНТНОГО СЛИТОГО БЕЛКА, ОБЛАДАЮЩЕГО АНТИ-IL-8 АКТИВНОСТЬЮ
WO2023125976A1 (zh) * 2021-12-31 2023-07-06 广州国家实验室 融合蛋白疫苗
CN116059388A (zh) * 2022-07-25 2023-05-05 国家纳米科学中心 一种多肽-化疗药物偶联物、其制备方法和应用
CN117003890B (zh) * 2023-08-09 2024-06-04 成都新诺明生物科技有限公司 一种含有P2和两个Fc的gE融合蛋白及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0906954A1 (en) 1997-09-29 1999-04-07 Applied Research Systems ARS Holding N.V. Amino-terminal truncated c-c chemokines as chemokine antagonist
CA2245224A1 (en) * 1998-08-14 2000-02-14 Jiang-Hong Giong Chemokine receptor antagonists and chemotherapeutics
WO2001078766A1 (de) 2000-04-13 2001-10-25 Bio Life Science Forschungs Und Entwicklungsgesellschaft Mbh Vakzine gegen krebserkrankungen, die sich auf mimotope von auf tumorzellen exprimierte antigenen stützt
AU2001259432B2 (en) * 2000-05-03 2005-04-21 Amgen Inc. Modified peptides, comprising an FC domain, as therapeutic agents
US7465790B2 (en) 2000-10-09 2008-12-16 Isis Innovation, Inc. Therapeutic antibodies
US20050002939A1 (en) * 2002-12-23 2005-01-06 Albert Zlotnik Tumor killing/tumor regression using CXCR4 antagonists
US20080108664A1 (en) 2005-12-23 2008-05-08 Liu Belle B Solid-state form of AMG 706 and pharmaceutical compositions thereof
FR2915102B1 (fr) * 2007-04-23 2014-05-16 Pf Medicament Utilisation d'un anticorps anti-cxcr4 pour le traitement du cancer
JP2010536335A (ja) 2007-08-13 2010-12-02 ファイザー・インク 活性が改善した組合せモチーフ免疫賦活性オリゴヌクレオチド

Similar Documents

Publication Publication Date Title
JP2013529178A5 (enExample)
JP2017160222A5 (enExample)
HRP20200370T1 (hr) Biokemijski stabilizirano hiv-1 trimer cjepivo
JP2017529059A5 (enExample)
HRP20190799T1 (hr) Imunocitokini na bazi il-15 i sushi domene il-15r alfa
HRP20130194T1 (hr) Imunosupresivni polipeptidi i nukleinske kiseline
JP7683932B2 (ja) ナチュラルキラー細胞を刺激するための組成物及び方法
JP2015509707A5 (enExample)
PT2697257T (pt) Proteínas de fusão fc compreendendo novos ligantes ou arranjos
JP2011521662A5 (enExample)
MX340014B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX340015B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX2012009000A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX340016B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
CA2663042A1 (en) Serum albumin binding proteins with long half-lives
WO2013055058A3 (ko) 항체결합 펩타이드-페리틴 융합단백질 및 이의 용도
JP2014506450A5 (enExample)
JP2011528222A5 (enExample)
CN107709355A (zh) 单链cd40受体激动剂蛋白
JP2013543384A5 (enExample)
JP2020519230A5 (enExample)
JP2016508143A5 (enExample)
CN108307642B (zh) 改造的白介素12及其在制备治疗肿瘤药物中的用途
JP2018512124A5 (enExample)
JP2014529399A5 (enExample)